Growth arrest and DNA-damage-inducible, beta (GADD45*β*) is a member of GADD45 family, and is originally cloned as a myeloid-differentiation primary-response gene (also named MyD118).^[@bib1]^ GADD45*β* is a small (18 kD) protein quickly induced by stressful factors, such as ultraviolet (UV) radiation^[@bib2]^ and hypoxia.^[@bib3]^ It has been reported that TNF-*α* treatment induces GADD45*β* protein expression through nuclear factor *κ*B (NF*κ*B)-mediated transcription,^[@bib4]^ and transforming growth factor-*β* induces its expression in Smad-dependent manner.^[@bib5]^ In contrast to proapoptotic effect of GADD45*α*,^[@bib6],\ [@bib7]^ GADD45*β* has been characterized as an anti-apoptotic protein. For example, GADD45*β* mediates hepatocyte survival during liver regeneration^[@bib8]^ and protects IL-1*β*-treated INS-1E cells from apoptosis.^[@bib9]^ GADD45*β*-deficient cell is more sensitive to UV-induced apoptosis.^[@bib2]^ Subsequent studies indicate that GADD45*β* can tightly bind to MAPK kinase 7 (MKK7) and attenuate its kinase activity, and in turn results in inactivation of MKK7/c-Jun N-terminal kinase (JNK) apoptotic pathway.^[@bib10],\ [@bib11]^ GADD45*β* expression synergistically represses cell growth through interaction with PCNA and p21,^[@bib12],\ [@bib13]^ and inhibits cdc2/cyclin B1 kinase activity and in turn induces G2/M arrest.^[@bib14]^ GADD45*β* can also directly bind to MTK1/MEKK4 and enhance those kinase autophosphorylation and activity,^[@bib15]^ and subsequently activate downstream kinases, JNK/p38.^[@bib15],\ [@bib16]^ Although anti-apoptotic effect of GADD45*β* is well-documented in previous studies, role of GADD45*β* in regulation of tumor-suppressor p53 expression and function has not been explored yet.

Tumor-suppressor p53 is a transcription factor responsible for transcriptional regulation of several key genes implicated in cell cycle control, DNA repair, and apoptosis.^[@bib17],\ [@bib18],\ [@bib19]^ Although GADD45*α* is a well-known p53-regulated gene,^[@bib20]^ GADD45*β* is identified as p53-independent gene.^[@bib2]^ Because p53 and GADD45*β* are response genes upon oxidative stress, elucidation of potential cross-talk between those two pathways will be essential for understanding of their biological significance in oxidative stress responses. Our current study found that GADD45*β* accelerated p53 protein degradation via targeting Src/protein phosphatase 2A (PP2A)/murine double minute 2 (MDM2) pathway.

Results
=======

GADD45*β* protected cells from death through JNK-independent pathway upon arsenite treatment
--------------------------------------------------------------------------------------------

GADD45*β* has been reported to protect hematopoietic cells from UV-induced apoptosis in JNK-dependent pathway,^[@bib2]^ and our previous study shows that arsenite treatment induces GADD45*β* protein expression.^[@bib6]^ To evaluate potential role and molecular basis of GADD45*β* induction in arsenite response, GADD45*β*+/+ and GADD45*β*−/− cells were employed. As shown in [Figure 1a](#fig1){ref-type="fig"}, arsenite treatment increased GADD45*β* protein expression in GADD45*β*+/+ cells, whereas as expected, there was no detectable GADD45*β* in GADD45*β*−/− cells. Our results also showed that arsenite exposure resulted in markedly cell death in a dose-dependent manner in GADD45*β*−/− cells, whereas GADD45*β*+/+ cells only showed a slightly morphological alteration and inhibition of cell growth under same experimental conditions ([Figure 1b](#fig1){ref-type="fig"}). Consistent with cell morphological alterations, flow-cytometry analysis suggested that arsenite treatment led to significant cell death in GADD45*β*−/− cells, whereas there was no detectable cell death in GADD45*β*+/+ cells under the same treatment ([Figure 1c](#fig1){ref-type="fig"}). This cell death was due to apoptosis because the cell death was consistent with the results obtained from detection of two well-characterized cell apoptotic markers, cleaved caspase 3 and cleaved poly (ADP-ribose) polymerase (PARP) ([Figure 1a](#fig1){ref-type="fig"}). Our results strongly suggested that GADD45*β* induction by arsenite did exhibit a protection from cell death. As published studies have shown that GADD45*β* suppressed cell apoptosis through directly binding to MKK7 and inhibiting JNK activation,^[@bib2],\ [@bib8],\ [@bib11]^ we compared MAPKs activation between GADD45*β*+/+ and GADD45*β*−/− cells following arsenite treatment. Consistent with previous reports, GADD45*β* deficiency (GADD45*β*−/−) resulted in increased JNK activation by arsenite in comparison with that in GADD45*β*+/+ cells ([Figure 2a](#fig2){ref-type="fig"}), and p38 and extracellular signal-regulated kinase (Erk) activation was also slightly elevated in GADD45*β*−/− cells ([Figure 2a](#fig2){ref-type="fig"}). To determine whether elevation of JNK activation had a role in the increased apoptosis upon arsenite treatment, a specific JNK inhibitor SP600125 was employed. The results showed that inhibition of JNK activation by SP600125 pretreatment did not show observable reduction of arsenite-induced apoptosis indicated by cleaved caspase 3 and cleaved PARP ([Figure 2b](#fig2){ref-type="fig"}). These results suggested that although JNK activation was elevated in GADD45*β*−/− cells, it did not contribute to increased sensitivity of GADD45*β*−/− cells to arsenite-induced apoptotic responses.

GADD45*β* promoted p53 protein degradation through elevating MDM2 phosphorylation in arsenite responses
-------------------------------------------------------------------------------------------------------

Our most recent study has shown that arsenite-induced p53 protein induction via p50 (NF*κ*B1)-mediated miR-190/PH-domain and leucine-rich repeat protein phosphatase 1/Akt pathway is essential for apoptotic response.^[@bib21]^ To test whether GADD45*β* participated in the regulation of p53 protein expression upon arsenite exposure, we evaluated p53 protein induction in both GADD45*β*+/+ and GADD45*β*−/− cells. As shown in [Figure 3a](#fig3){ref-type="fig"}, arsenite-induced p53 protein level was remarkably increased in GADD45*β*−/− cells compared with that in GADD45*β*+/+ cells. It has been known that p53 phosphorylation at Ser15 attenuated its binding with MDM2 and enhanced p53 protein accumulation.^[@bib22]^ Thus, we also determined p53 phosphorylation at Ser15 in both cell lines. The results showed that consistent with total p53 protein expression, p53 phosphorylation at Ser15 was also elevated in GADD45*β*−/− cells. The results obtained from determination of p53 mRNA levels in both cell lines strongly revealed that p53 mRNA level was regulated by neither arsenite treatment nor GADD45*β* expression ([Figure 3b](#fig3){ref-type="fig"}), suggesting that GADD45*β* might mediate p53 protein expression at either protein degradation or translation. We therefore compared p53 protein-degradation rates between GADD45*β*+/+ and GADD45*β*−/− cells. The data showed that p53 protein-degradation rate in GADD45*β*−/− cells was much slower than that in GADD45*β*+/+ cells ([Figure 3c](#fig3){ref-type="fig"}), and arsenite treatment could delay p53 protein degradation in both cell lines ([Figure 3c](#fig3){ref-type="fig"}). In contrast to p53 protein, p21 protein degradation was faster in GADD45*β*−/− cells as compared with that in GADD45*β*+/+ cells ([Figure 3c](#fig3){ref-type="fig"}). It has been well known that MDM2 phosphorylation at Ser166 increases its binding activity to p53 protein and mediates p53 protein degradation.^[@bib22],\ [@bib23]^ So we compared MDM2 phosphorylation at Ser166 between the GADD45*β*+/+ and GADD45*β*−/− cells following arsenite treatment. The results indicated that MDM2 phosphorylation at Ser166 was much lower in GADD45*β*−/− cells in comparison with that in GADD45*β*+/+ cells ([Figure 3d](#fig3){ref-type="fig"}), however, GADD45*β* deletion did not affect total MDM2 expression ([Figure 3d](#fig3){ref-type="fig"}), suggesting that GADD45*β* regulated p53 protein degradation via mediating MDM2 protein phosphorylation at Ser166, rather than affecting total MDM2 expression.

To determine whether the upregulation of p53 protein expression, and p53 phosphorylation at Ser15, in GADD45*β*−/− cells could mediate p53-regulated gene expression, we also evaluated expression of GADD45*α*, Bax and PUMA in both GADD45*β*+/+ and GADD45*β*−/− cells. The results showed that GADD45*α* protein expression was markedly increased in GADD45*β*−/− cells in comparison with that in GADD45*β*+/+ cells ([Figure 3a](#fig3){ref-type="fig"}), whereas there was no observable difference of Bax and PUMA protein expression between GADD45*β*+/+ and GADD45*β*−/− cells following arsenite exposure, although arsenite treatment showed an increased PUMA protein expression and no effect on Bax protein expression in both cell lines ([Figure 3a](#fig3){ref-type="fig"}). Consistent with their protein expression, the mRNA levels of *bax* and *puma* was comparable between GADD45*β*+/+ and GADD45*β*−/− cells ([Figure 3b](#fig3){ref-type="fig"}). Our previous study has demonstrated that arsenite treatment induces apoptotic response via p50/GADD45*α*/JNK-dependent mitochondrial pathway.^[@bib6]^ Most recently, it has also been reported that arsenite could promoted human neural stem cell apoptosis through mitochondria-dependent signal pathway.^[@bib24]^ Although Bax and PUMA are reported to have essential role in mitochondria-dependent cell apoptotic responses,^[@bib25]^ Bax-independent apoptotic pathways have also been reported in previous studies. For example: Panton--Valentine leukocidin could directly target to mitochondria and induce Bax-independent cell apoptosis,^[@bib26]^ and serum withdrawal-induced apoptosis could also be observed in Bax/Bak double-knockout cells.^[@bib27]^ To further exclude the potential involvement of Bax and PUMA in the apoptotic responses by arsenite, the HCT116 Bax−/− and HCT116 PUMA−/− cells were employed. The results indicated that deletion of either Bax or PUMA ([Figure 3e](#fig3){ref-type="fig"}) did not show observable reduction of caspase 3 cleavage following arsenite treatment ([Figure 3f](#fig3){ref-type="fig"}). Taken together, our results suggested that arsenite-induced apoptosis might be mediated via GADD45*α*-dependent and Bax- and PUMA-independent mitochondrial pathway.

GADD45*β* mediated MDM2 phosphorylation at Ser166 via regulation of PP2A phosphorylation at Tyr307
--------------------------------------------------------------------------------------------------

MDM2 phosphorylation at Ser166 is regulated by multiple pathways.^[@bib23],\ [@bib28]^ MEK/Erk activation has been reported to positively regulate MDM2 phosphorylation at Ser166 in HepG2 cells.^[@bib23]^ Phophoinositide 3-kinase (PI3K)/Akt also has an important role in modulation of MDM2 phosphorylations at Ser166 and Ser186.^[@bib28]^ The results obtained from our comparison of Akt activation did not show any observable difference between GADD45*β*+/+ and GADD45*β*−/− cells following arsenite treatment, whereas Erk phosphorylation induced by arsenite was slightly increased in GADD45*β*−/− cells ([Figure 4a](#fig4){ref-type="fig"}). Thus, we anticipated that both Erk and Akt might not participate in GADD45*β*-regulated MDM2 phosphorylation at Ser166. Phosphotase PP2A is consisted of regulatory subunits A and B, and catalytic subunit C,^[@bib29]^ and has been shown to be implicated in dephosphorylation of MDM2 at Ser166.^[@bib30]^ C subunit phosphorylation at Tyr307 negatively regulates PP2A catalytic activity.^[@bib29]^ Our data revealed that arsenite treatment led to marked increase in PP2A C subunit phosphorylated at Tyr307 in GADD45*β*+/+ cells, while it was attenuated in GADD45*β*−/− cells under same experimental conditions ([Figure 4b](#fig4){ref-type="fig"}). Moreover, there was no difference on total PP2A C subunit protein levels between two cell lines ([Figure 4b](#fig4){ref-type="fig"}). To identify whether PP2A protein binds to MDM2 protein, co-immunoprecipitation was performed to pull down MDM2 protein using specific anti-MDM2 antibody. As shown in [Figure 4c](#fig4){ref-type="fig"}, PP2A C subunit was detected in immunocomplex pull down with anti-MDM2 antibody. Importantly, more PP2A protein presented in the immunocomplex showed an inverse correlation with levels of p-MDM2 at Ser166 ([Figure 4c](#fig4){ref-type="fig"}), consistently supporting our notion that PP2A is a phosphotase targeting p-MDM2 at Ser166. Moreover, arsenite treatment attenuated PP2A binding to MDM2 in GADD45*β*+/+ cells, whereas it increased this binding in GADD45*β*−/− cells ([Figure 4c](#fig4){ref-type="fig"}). To detect PP2A function in regulating MDM2 phosphorylation at Ser166 and p53 expression, okadaic acid (OA),^[@bib31]^ the inhibitor of PP2A was employed. As shown in [Figure 4d](#fig4){ref-type="fig"}, the phosphorylation of MDM2 at Ser166 was markedly increased in GADD45*β*−/− cells upon OA treatment for 12 h, whereas arsenite-induced p53 protein expression was reduced in same experimental conditions. Our study demonstrated that GADD45*β* had an important role in downregulation of PP2A interaction and regulation of MDM2 functions following arsenite exposure.

GADD45*β* regulated Src phosphorylation following arsenite exposure
-------------------------------------------------------------------

It has been found that Src, a non-receptor tyrosine kinase, has a key role in regulation of PP2A C subunit phosphorylation and its function.^[@bib32],\ [@bib33]^ Src kinase activity is positively regulated by its autophosphorylation at Tyr416, whereas it is negatively regulated by phosphorylation at Tyr527.^[@bib33]^ To test potential involvement of Src activation in GADD45*β* regulating PP2A phosphorylation, we compared Src phosphorylation status between GADD45*β*+/+ and GADD45*β*−/− cells following arsenite exposure. The results, as expected, showed that in GADD45*β*+/+ cells, p-Src Tyr416 was remarkably increased after arsenite treatment ([Figure 4e](#fig4){ref-type="fig"}), whereas this phosphorylation was dramatically downregulated in GADD45*β*−/− cells ([Figure 4e](#fig4){ref-type="fig"}). In addition, phosphorylated Src at Tyr527 had no dramatic change in GADD45*β*+/+ cells, but markedly increased in GADD45*β*−/− cells upon arsenite treatment ([Figure 4e](#fig4){ref-type="fig"}). These results revealed that GADD45*β* depletion resulted in downregulation of Src activity. As Src regulation of PP2A phosphorylation is well characterized in previous studies, we anticipate that increased Src activity in GADD45*β*+/+ cells might be responsible for reduction of PP2A phosphorylation and activity. Thus, small interfering RNA specific to mouse Src (siSrc) were transfected into GADD45*β*+/+ cells, and the stable transfectants were identified after puromycin selection. As shown in [Figure 4f](#fig4){ref-type="fig"}, Src expression was markedly knockdown in GADD45*β*+/+ (siSrc) cells in comparison with that in GADD45*β*+/+ (nonsense) cells. Consistently, the phosphorylation of PP2A at Tyr307 was also dramatically decreased in GADD45*β*+/+ (siSrc) cells as compared with that in control cells ([Figure 4f](#fig4){ref-type="fig"}), whereas the p-MDM2 at Ser166 was attenuated and the p53 and p-p53 at Ser15 were subsequently upregulated in GADD45*β*+/+ (siSrc) cells upon arsenite treatment ([Figure 4f](#fig4){ref-type="fig"}). Taken together, our results demonstrated that PP2A was involved in downregulation of MDM2 phosphorylation at S166, which led to p53 protein accumulation in GADD45*β*−/− cells possibly through suppressing Src function.

Elevation of p53 expression in GADD45*β*−/− cells was responsible for increased sensitivity of apoptotic response following arsenite treatment
----------------------------------------------------------------------------------------------------------------------------------------------

To test whether p53 upregulation rendered the increased arsenite apoptotic response in GADD45*β*−/− cells, small interfering RNA targeting mouse p53 was transfected into GADD45*β*−/− cells, and stable transfectant GADD45*β*−/− (sip53) and its no-silencing vector control transfectant GADD45*β*−/− (vector) were established and identified as indicated in [Figure 5c](#fig5){ref-type="fig"}. Arsenite-induced cell death was dramatically inhibited in GADD45*β*−/− (sip53) compared with GADD45*β*−/− (vector) cells ([Figures 5a and b](#fig5){ref-type="fig"}). Cell apoptosis induced by arsenite was dramatically reduced as indicated by cleaved caspase 3 and PARP ([Figure 5c](#fig5){ref-type="fig"}). The results strongly demonstrated that p53 protein upregulation in GADD45*β*−/− cells mediated the increased apoptotic response due to arsenite treatment.

Discussion
==========

p53 is a well-known tumor-suppressor gene, and has an essential role in regulating cell apoptosis upon oxidative stresses.^[@bib34]^ Previous study has reported that arsenite induces cell apoptosis in p53-dependent pathway.^[@bib35]^ Furthermore, the studies from us and other groups have shown that arsenite treatment fails to upregulate either wild-type or mutant p53 transcription,^[@bib36],\ [@bib37]^ whereas arsenite treatment promotes mutant p53 protein degradation.^[@bib37]^ In current study, GADD45*β* depletion alleviated p53 protein degradation via suppressing MDM2 phosphorylation at Ser166 upon arsenite exposure. MDM2 recognizes and binds to the N-terminal transactivation domain of p53. This binding not only inhibits p53-dependent transcriptional activity and its translocation^[@bib38]^ but also functions as an E3 ligase and mediates p53 protein degradation via 26S proteasome.^[@bib39]^ p53 is stabilized by phosphorylation at N-terminal residues Ser15 and Ser20, which alleviated its interaction with MDM2.^[@bib22],\ [@bib40]^ MDM2 phosphorylation at Ser395, Ser407 or Thr216 has also been reported to inhibit p53 transfer from nucleus to cytoplasm;^[@bib30],\ [@bib31],\ [@bib41]^ whereas p-MDM2 at Ser166 enhances its interaction with p53 and promotes p53 protein degradation via MEK/Erk or PI3K/Akt pathway.^[@bib23],\ [@bib28]^ Bax and PUMA, which are implicated in mitochondria-dependent cell apoptosis, are also the important downstream genes of p53.^[@bib25]^ PUMA could trigger Bax to translocate into mitochondria and subsequently promote cytochrom-*c* release, and in turn mediates the mitochondria-dependent cell apoptosis.^[@bib42],\ [@bib43]^ However, Bax-independent apoptotic pathways have also been reported in previous studies.^[@bib26],\ [@bib27]^ It has been reported that Panton--Valentine leukocidin could directly target to mitochondria and induce Bax-independent cell apoptosis,^[@bib26]^ and serum withdrawal-induced apoptosis could also be observed in Bax/Bak double-knockout cells.^[@bib27]^ In current study, the differential expression of Bax and PUMA in both protein and mRNA levels was not observed between GADD45*β*+/+ and GADD45*β*−/− cells following arsenite exposure, and further knockout of either *bax* or *puma* did not inhibit arsenite-induced apoptosis. Collectively, we anticipate that GADD45*β* induction negatively regulated p53 protein accumulation following arsenite treatment through its positive regulation of MDM2 phosphorylation at Ser166, and inhibits cell apoptosis via Bax/PUMA-independent manner.

PP2A is a serine/threonine phosphatase, which consists of two regulatory subunits (A and B) and one catalytic subunit (C).^[@bib29]^ It has been reported that PP2A is able to use MDM2 as a substrate and dephosphorylates MDM2 at Ser166.^[@bib30]^ Moreover, knockdown of PP2A C subunit increases p-MDM2 at Ser166 and attenuates diosmin-induced p53 protein expression.^[@bib44]^ Src is a kinase that mediates PP2A phosphorylation at Tyr307, which inactivates PP2A activity.^[@bib32]^ Src consists of a N-terminal SH3 domain, a central SH2 domain and a tyrosine kinase domain.^[@bib45]^ Its phosphorylation at Tyr527 by C-terminal Src kinase (CSK) or CSK homology kinase enhances intra-molecularly interaction with SH2 domain, and this interaction conflicts with its autophosphorylation at Tyr416, which activates tyrosine kinase domain.^[@bib45]^ Our results showed that GADD45*β* depletion increased arsenite-induced Src phosphorylation at Tyr527 and decreased its phosphorylation at Tyr416 ([Figure 4e](#fig4){ref-type="fig"}), indicating that GADD45*β* expression provided an inhibitory effect on Src phosphorylation at Tyr527, and further led to elevation of its phosphorylation at Tyr416 and subsequently upregulation of Src kinase activity. It has been reported that GADD45*β* deletion results in protein kinase A (PKA) activation upon arsenite treatment.^[@bib46]^ PKA is an important cyclic adenosine monophosphate^[@bib47]^-dependent kinase, and can elevate CSK activation and subsequently enhance p-Src at Tyr527.^[@bib48]^ Our results showed that arsenite treatment induced GADD45*β* protein expression, which might result in PKA inactivation, and in turn further inhibiting Src phosphorylation at Tyr527, and elevating Src phosphorylation at Tyr416, and subsequently upregulating Src kinase activity in GADD45*β*+/+ cells. The activated Src mediates p-PP2A at Tyr307, and then attenuates PP2A activity. The GADD45*β*-mediated inactivation of PP2A further results in reduction of its interaction with MDM2 and increased MDM2 phosphorylation at Ser166, and MDM2-mediated p53 protein degradation.

As an important anti-apoptosis gene, GADD45*β* implicates in regulating cell apoptosis and cancer therapy in many previous studies. NF*κ*B is a key transcription factor responsible for regulation of GADD45*β* expression.^[@bib4]^ Metallopanstimulin-1, the regulator of NF*κ*B activation, inhibits human gastric cancer cell apoptosis by elevating GADD45*β* expression in NF*κ*B-dependent manner.^[@bib49]^ Antitumor drug parthenolide induces breast cancer cell apoptosis by inhibiting NF*κ*B activation and GADD45*β* expression.^[@bib47]^ Another regulator of GADD45*β* expression is the nuclear receptor constitutive active/androstane receptor (CAR),^[@bib50]^ and subsequent study shows that CAR can attenuate TNF-*α*-induced hepatocellular carcinoma cell apoptosis through forming complex with GADD45*β* and repressing MKK7/JNK activity.^[@bib51]^ GADD45*β* also protects against INS-1E cell apoptosis upon IL-1*β* treatment through downregulating JNK and Erk activation.^[@bib9]^ In this study, we found that GADD45*β* provided a protective effect on arsenite-induced cell death in a JNK-independent manner via mediating p53 protein degradation. As a target gene of p53,^[@bib20]^ GADD45*α* is involved in promoting arsenite-induced cell apoptosis via JNK-dependent pathway.^[@bib6]^ Our current study showed that GADD45*α* protein induction was observed accompanied with increased p53 protein accumulation in GADD45*β*−/− cells upon arsenite treatment ([Figure 3a](#fig3){ref-type="fig"}); and knockdown of p53 expression also profoundly attenuated GADD45*α* protein induction in GADD45*β*−/− cells ([Figure 5c](#fig5){ref-type="fig"}). Thus, our data provide a novel evidence demonstrating a cross-talk between GADD45*β* and GADD45*α* upon oxidative stress: with arsenite treatment, activated IKK/NF*κ*B mediates GADD45*β* induction, and GADD45*β* induction by arsenite implicates in elevating p53 protein degradation, which represses its target gene GADD45*α* expression, and further inhibits cell apoptosis, whereas IKK/NF*κ*B1(p50) mediates GADD45*α* protein accumulation and induces cell apoptosis through activating JNK signal pathway.^[@bib6]^ Thus, the balance of GADD45*α* and GADD45*β* expression and their cross-talk in their expression regulation has a pivotal role in determination of cell death and survival.

Arsenite is a well-known carcinogen, and long-term exposure to low-dose arsenite ingested from drinking water is associated with high risk of many cancers, including liver, skin, lung, and kidney cancer.^[@bib52]^ Our *in vitro* studies also demonstrate that chronic exposure of cells to low-dose arsenite leads to cell transformation in mouse Cl41, human keratinocyte, and human bronchial epithelial Bease-2B cells.^[@bib53],\ [@bib54],\ [@bib55]^ Our current study found that GADD45*β* induction by arsenite mediated an inhibitory effect on p53 protein accumulation, by which it protected cells from death. Because cell death is an important response against oncogenesis by eliminating genetically damaged cells following oxidative stress,^[@bib56]^ we anticipate that GADD45*β* induction by arsenite might be associated with carcinogenic effect of arsenite chronic exposure.

In conclusion, our study demonstrates that GADD45*β* induction increases p53 protein degradation through inhibiting MDM2 phosphorylation at Ser166 in Src/PP2A-dependent pathway following arsenite treatment. It is the first time, to the best of our knowledge, to demonstrate that GADD45*β* is implicated in regulating p53 protein degradation, and this novel finding facilitates our understanding of the mechanisms involved in the GADD45*β* regulation of cell death and provides evidence, indicating that the cross-talk between GADD45*α* and GADD45*β* in the regulation of their protein expression is essential for determination of cell death and survival in oxidative stress, such as arsenite exposure.

Materials and Methods
=====================

Plasmids, antibodies and other reagents
---------------------------------------

Mouse small interfering RNA specific to p53 (sip53) and its scramble vector were constructed and reported in our previous studies.^[@bib57]^ The constructs of shRNA-targeting mouse Src (siSrc) and its nonsense vector were kind gift from Dr. Gary E. Gallick (Department of Cancer Biology, M.D. Anderson Cancer Center, University of Texas).^[@bib58]^ The antibodies specific against p53, p-p53 Ser15, Akt, p-Akt Thr308, phosphatase and tensin homolog, JNK, p-JNK at Thr183/Tyr185, p38, p-p38 at Thr180/Tyr182, Erk, p-Erk Thr202/Tyr204, p-MDM2 Ser166, Src, p-Src Tyr416, N-p-Src Tyr416, p-Src Tyr527, N-p-Src Tyr527, p-PP2A Tyr307, Bax, PUMA, PARP, and caspase 3 were purchased from Cell Signaling Technology (Beverly, MA, USA). Antibodies specific against GADD45*α*, GADD45*β*, MDM2, and p21 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). *β*-Actin antibody was bought from Sigma (St. Louis, MO, USA). PP2A antibody was purchased from Epitomics (Burlingame, CA, USA). Chemicals of MG132, CHX, and SP600125 were purchased from Calbiochem (San Diego, CA, USA). PP2A inhibitor OA was purchased from LC laboratories (Woburn, MA, USA).

Cell culture and transfectants
------------------------------

GADD45*β*+/+ and GADD45*β*−/− mouse embryonic fibroblasts were derived from GADD45*β*+/+ and GADD45*β*−/− mice as described,^[@bib59]^ and cultured in DMEM medium. The human colon cancer cells HCT116, HCT116/Bax−/− and HCT116/PUMA−/−, as previously described,^[@bib60]^ were cultured in McCoy\'s 5A medium. All cells and their transfectants were cultured in corresponding medium supplied with 10% FBS, 1% penicillin/streptomycin, and 2 mM ℒ-glutamine (Life Technologies, Grand Island, NY, USA) in 37 °C incubator with 5% CO~2~. The shRNA-targeting mouse p53 (sip53) or its scramble vector was transfected into GADD45*β*−/− cells with pSUPER-LacZ, and stable transfectants were selected using hygromycin (Cellgro, Manassas, VA, USA). SiSrc or its vector together with pSUPER-puro was used to transfect GADD45*β*+/+ cells. The stable transfectants were selected by puromycin (Cellgro). And all transfectants were mediated by PolyJet DNA *in Vitro* Transfection Reagent (SignaGen Laboratories, Rockville, MD, USA).

Reverse transcription PCR
-------------------------

Cells treated by arsenite with indicated doses for 6 h were subjected to total RNA extraction using TRIzol reagent (Invitrogen, Grand Island, NY, USA) following the manufacturer\'s instructions. Total RNA (5 *μ*g) was used for first-strand cDNA synthesis with oligdT~(20)~ primer by SuperScript III First-Strand Synthesis system (Invitrogen). Specific primers (Invitogen) for mouse *p53* (forward: 5′-CAC GTA CTC TCC TCC CCT CA-3′, reverse: 5′-CTT CTG TAC GGC GGT CTC TC-3′), *bax* (forward: 5′-TCG AGC AGG GAG GAT GGC TG-3′, reverse: 5′-TTC CCA GCC ACC CTG GTC TT-3′), *puma* (forward: 5′-CTC AGC CCT CCC TGT CAC CA-3′, reverse: 5′-CGC CGC TCG TAC TGC GCG TT-3′), and *β-actin* (forward: 5′-CCT GTG GCA TCC ATG AAA CT-3′, reverse: 5′-GTG CTA GGA GCC AGA GCA GT-3′) were used for PCR amplification.

Protein-degradation assay
-------------------------

GADD45*β*+/+ and GADD45*β*−/− cells were seeded into six-well plate, respectively. When cell confluence reached 70--80%, MG132 (10 *μ*M) was used to pretreat cells for 4 h, and then the medium was replaced with fresh medium containing 10 *μ*M CHX with or without 10 *μ*M arsenite and cells were cultured for indicated time periods. The cells were extracted and subjected to western blotting for determination of p53 protein levels.

Immunoprecipitation
-------------------

To determine PP2A interaction with MDM2, GADD45*β*+/+ and GADD45*β*−/− cells were cultured in 10-cm dishes till 70--80% confluence. Then, cell culture medium was replaced with 0.1% FBS DMEM and cultured for 12 h. Cells were then treated with arsenite for 9 h. Cell lysate was collected with IP buffer (25 mM Tris-HCl, pH7.5, 1 mM DTT, 30 mM MgCl~2~, 40 mM NaCl, 0.5% NP-40, and protease inhibitor). Total protein (1 mg) from each sample was subjected to immunoprecipitation using antibodies specific against MDM2 (anti-MDM2; Sigma) or control mouse IgG together with protein A/G plus agarose (Santa Cruz Biotechnology). Agarose were collected after centrifugation (5000 × *g*, 2 min) at 4 °C and washed using IP buffer for 4--5 times. SDS sample buffer (2 × ) was used to extract the proteins from agarose beads for western blotting.

Flow cytometry
--------------

Cells were seeded into six-well plates and cultured until 70--80% confluence. The cell culture medium was replaced with 0.1% FBS DMEM and cultured for another 12 h, and the cells were then exposed to arsenite as indicated. All cells were collected by centrifugation at 1500 r.p.m. for 5 min. The cell pellets were washed by ice-cold PBS, following by fixing in ice-cold 70% ethanol at −20 °C overnight. Then, cells were washed with PBS 2--3 times and cell death was analyzed using flow cytometry (Beckman, Indianapolis IN, USA) after incubating with PI buffer (0.1% Triton X-100, 0.2 mg/ml RNase A, and 0.05 mg/ml PI) for 15 min.

Western blotting
----------------

Cells were seeded into six-well plates and cultured until 70--80% confluent. The cell culture medium was replaced with 0.1% FBS medium for 12 h and then subjected to arsenite treatment as indicated time period. The cells were extracted with cell lysis buffer (10 mM Tris-HCl, pH 7.4, 1% SDS, 1 mM Na~3~VO~4~, and proteasome inhibitor), and protein concentration was determined by Nano Drop 2000 (Thermo Scientific, Holtsville, NY, USA). Protein extract (30--60 *μ*g/sample) was subjected to SDS-PAGE gel, and western blotting was carried out as described in our previous report.^[@bib6]^
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![GADD45*β* protected arsenite-treated cells from death. GADD45*β*+/+ and GADD45*β*−/− cells were seeded into six-well plate till 80% confluent. The cell culture medium was replaced with 0.1% FBS DMEM for 12 h and then subjected to arsenite treatment at indicated doses. (**a**) The cells were extracted, and protein samples were subjected to western blotting with specific antibodies as indicated. (**b**) Cell morphology images were taken under microscope. (**c**) Cells were subjected to flow-cytometry analysis as described in Materials and Methods](cddis2013162f1){#fig1}

![GADD45*β* exhibited its protective effect through JNK-independent pathway following arsenite treatment. (**a**) GADD45*β*+/+ and GADD45*β*−/− cells were seeded into six-well plate till 80% confluent. The cell culture medium was replaced with 0.1% FBS DMEM for 12 h and then subjected to arsenite treatment for 3 h as indicated. The cells were extracted, and protein samples were subjected to western blotting with specific antibodies against total and phosphorylated MAPKs. (**b**) GADD45*β*−/− cells were seeded into six-well plate. The cells were pretreated with SP600125 for 30 min and were then exposed to arsenite as indicated. Cell extracts were subjected to western blotting with specific antibodies as indicated](cddis2013162f2){#fig2}

![GADD45*β* depletion stabilized p53 protein through dephosphorylating MDM2. (**a**) GADD45*β*+/+ and GADD45*β*−/− cells were exposed to arsenite as indicated dose for 12 h. The cell extracts were subjected to western blotting with specific antibodies against p-p53 Ser15, p53, GADD45*α*, Bax, and PUMA. (**b**) After arsenite treatment for 6 h, total RNA was extracted, and reverse transcription was performed as described in Materials and Methods. *Bax*, *puma*, and *p53* mRNA level in GADD45*β*+/+ and GADD45*β*−/− cells with or without arsenite treatment was analyzed by PCR. (**c**) GADD45*β*+/+ and GADD45*β*−/− cells were seeded into six-well plate and were then pretreated with 10 *μ*M of MG132 for 4 h. The cell culture medium was replaced by fresh medium containing 10 *μ*M CHX with or without arsenite as indicated. The cells were extracted for determination of p53 and p21 protein levels at time points as indicated. (**d**) GADD45*β*+/+ and GADD45*β*−/− cells were treated by 10 *μ*M of arsenite for indicated time, and cell extracts were subjected to western blotting with specific antibodies against p-MDM2 Ser166 or MDM2. (**e** and **f**) The cells of HCT116, HCT116/Bax−/− and HCT116/PUMA−/− were identified (**e**), and the expressions of caspase3 and cleaved caspase3 in these three cells with or without arsenite treatment as indicated dose were detected using western blotting assay (**f**)](cddis2013162f3){#fig3}

![GADD45*β*-mediated p53 protein degradation via regulating PP2A/MDM2 pathway. (**a**, **b** and **e**) GADD45*β*+/+ and GADD45*β*−/− cells were exposed to arsenite, and cell extracts were subjected to western blotting with indicated specific antibodies. (**c**) Total cell lysate of GADD45*β*+/+ and GADD45*β*−/− cells with the indicated treatment for 9 h was subjected to co-immunoprecipitation assay using *α*-MDM2 antibody. Immunocomplex samples were further subjected to western blotting with specific antibodies against MDM2, p-MDM2 Ser166, and PP2A C subunit. (**d**) GADD45*β*−/− cells seeded into six-well plate were pretreated with OA for 30 min and then exposed to arsenite for 12 h. The cell extracts were subjected to western blotting with specific antibodies against p53 and MDM2. (**f**) Stable transfectants of GADD45*β*+/+(nonsense) and GADD45*β*+/+(siSrc) were seeded into six-well plates. When cell confluence reached 70--80%, cell culture medium was replaced with 0.1% FBS DMEM and cultured for 12 h. The cells were then exposed to arsenite for another 12 h. Cell extracts were subjected to western blotting](cddis2013162f4){#fig4}

![p53 protein accumulation in GADD45*β*-depletion cells had a role in arsenite-induced cell death. The construct of mouse interfering RNA specific to p53 (sip53) and its empty vector were stably transfected into GADD45*β*−/− cell. After starvation, the stable transfectants were exposed to arsenite for 12 h. (**a**) The cell morphology images were taken under microscope. (**b**) Cells were collected and subjected to flow cytometry for determination of cell death with PI staining. (**c**) The cells were extracted and subjected to western blotting with indicated specific antibodies](cddis2013162f5){#fig5}
